biostudies-literatureUnknown12Feng AW<h4>Background</h4>The purpose was to compare the efficacy and safety of hepatic arterial infusion (HAI) of oxaliplatin plus raltitrexed (TOMOX) to those of oxaliplatin plus 5-fluorouracil (FOLFOX) for unresectable colorectal cancer liver metastases (CRCLM).<h4>Methods</h4>Patients with unresectable CRCLM were randomly assigned to receive HAI of TOMOX or FOLFOX. The primary end points were progression-free survival (PFS) measured from the date of randomisation until the date of disease progression and objective response rate (ORR). The secondary end points were overall survival (OS) measured from the date of randomisation until the date of death from any cause, disease control rate (DCR), and adverse events.<h4>Results</h4>113 patients were randomly assigned. With a median follow-up of 39.Frontiers in oncology913017https://www.ebi.ac.uk/biostudies/studies/S-EPMC9532863biostudies-literatureA randomized phase II trial of hepatic arterial infusion of oxaliplatin plus raltitrexed versus oxaliplatin plus 5-fluorouracil for unresectable colorectal cancer liver metastases.PMC9532863Liu SXFeng AWCao GGuo JHLiu PWang XDZhu XChen HKou FXXu HFGao SfalseA randomized phase II trial of hepatic arterial infusion of oxaliplatin plus raltitrexed versus oxaliplatin plus 5-fluorouracil for unresectable colorectal cancer liver metastases.<h4>Background</h4>The purpose was to compare the efficacy and safety of hepatic arterial infusion (HAI) of oxaliplatin plus raltitrexed (TOMOX) to those of oxaliplatin plus 5-fluorouracil (FOLFOX) for unresectable colorectal cancer liver metastases (CRCLM).<h4>Methods</h4>Patients with unresectable CRCLM were randomly assigned to receive HAI of TOMOX or FOLFOX. The primary end points were progression-free survival (PFS) measured from the date of randomisation until the date of disease progression and objective response rate (ORR). The secondary end points were overall survival (OS) measured from the date of randomisation until the date of death from any cause, disease control rate (DCR), and adverse events.<h4>Results</h4>113 patients were randomly assigned. With a median follow-up of 39.2022-01-01T00:00:00Z20222025-05-29T16:10:25.471Z2025-04-05T07:08:41.404ZS-EPMC95328633621250410.3389/fonc.2022.913017